These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15261686)

  • 41. Aggressive lipid reduction provides additional clinical benefit.
    Am J Manag Care; 2002 Jul; Suppl Symposium Reporter():1, 4. PubMed ID: 12608148
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
    Betteridge DJ; Gibson JM; Sager PT
    Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update on lipid-lowering therapy and LDL-cholesterol targets.
    Wiviott SD; Cannon CP
    Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):424-36. PubMed ID: 16874355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. From the Editor.
    Levy D
    J Am Soc Hypertens; 2017 Jan; 11(1):1-2. PubMed ID: 28284386
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
    MMW Fortschr Med; 2005 Aug; 147(33-34):51. PubMed ID: 16138641
    [No Abstract]   [Full Text] [Related]  

  • 47. Vascular health: the emerging appreciation of the endothelium.
    Talley JD
    J Ark Med Soc; 1997 Feb; 93(9):454-5. PubMed ID: 9046759
    [No Abstract]   [Full Text] [Related]  

  • 48. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Ezetimibe--intestinal cholesterol absorbtion inhibitor].
    Pikto-Pietkiewicz W; Pasierski T
    Kardiol Pol; 2006 Dec; 64(12):1434-41. PubMed ID: 17206545
    [No Abstract]   [Full Text] [Related]  

  • 51. Changing face of dyslipidemia therapy.
    Banerjee AK
    Indian Heart J; 2008; 60(3):192-4. PubMed ID: 19240305
    [No Abstract]   [Full Text] [Related]  

  • 52. C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis.
    Rosenau BJ; Costenbader KH; Schur PH
    Vasc Med; 2008 Feb; 13(1):25-8. PubMed ID: 18372435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [About: pleiotropic effects of statins in atherosclerosis].
    Ambrosi P
    Arch Mal Coeur Vaiss; 2005 Dec; 98(12):1263; author reply 1263-5. PubMed ID: 16435610
    [No Abstract]   [Full Text] [Related]  

  • 54. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.
    Davidson MH
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1582-3. PubMed ID: 18716322
    [No Abstract]   [Full Text] [Related]  

  • 55. [Ultra low levels of low density lipoprotein cholesterol in primary prevention in subjects with elevated C-reactive protein. Results of JUPITER].
    Gratsianskiĭ NA
    Kardiologiia; 2009; 49(1):73-5. PubMed ID: 19166407
    [No Abstract]   [Full Text] [Related]  

  • 56. JUPITER study highlights C-reactive protein as a cardiac risk factor.
    Cardiovasc J Afr; 2009; 20(2):146. PubMed ID: 19421655
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of C-reactive protein (CRP) and statin treatment in reducing cardiovascular risk.
    Chin J
    S D Med; 2009 Mar; 62(3):104-6. PubMed ID: 19480274
    [No Abstract]   [Full Text] [Related]  

  • 58. Getting more people on statins.
    Roberts WC
    Am J Cardiol; 2002 Sep; 90(6):683-5. PubMed ID: 12231110
    [No Abstract]   [Full Text] [Related]  

  • 59. [Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study].
    Comaschi MA; Menozzi F
    Ital Heart J Suppl; 2001 May; 2(5):556-8. PubMed ID: 11388336
    [No Abstract]   [Full Text] [Related]  

  • 60. Statin fails to meet expectations.
    Traynor K
    Am J Health Syst Pharm; 2003 Feb; 60(3):233. PubMed ID: 12613230
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.